Traditionally, it was felt that the INR had to be less than 1.5 and platelets had to be at least 50,000/µL to perform most bedside procedures. With more clinical evidence, we now know that low-risk bedside procedures can be performed…
Read More
More Articles – Anticoagulation, antiplatelets, epidural hematoma, Featured, HPC update, Lumbar Puncture
More Tags – anticoagulation, antiplatelets, epidural hematoma, featured, HPC updates, lumbar puncture
This blog summarizes the guidelines by the European Society of Anesthesiology (ESA), the American Society of Regional Anesthesia (ASRA) and the Association of British Neurologists regarding the timing of antiplatelet and anticoagulation discontinuation before a lumbar puncture. The following table…
Read More
More Articles – Anticoagulation, antiplatelets, central lines, Chest tube, chest tubes, coagulopathy, Featured, HPC update, Lumbar Puncture, Paracentesis, procedures, Thoracentesis
This blog summarizes the 2019 Society of Interventional Radiology (SIR) for Periprocedural Management of Image-guided Procedures with regards to thrombocytopenia, coagulopathies, antiplatelets and anticoagulation. The SIR guidelines are summarized as follows: Anticoagulation with heparin, LMWH, fondaparinux, argatroban, warfarin, DOAC, clopidogrel, ticagrelor…
Read More
The optimal treatment of portal vein thrombosis in patients with cirrhosis has been a topic of debate for quite some time. To this date there have been no large prospective, randomized controlled trials to help guide management in these patients. …
Read More
More Articles – Anticoagulation, Cancer, Deep vein thrombosis, DVT, HPC Updates, Updated guidelines, Venous Thromboembolic Disease, VTD
Every four years the American College of Chest Physicians (ACCP) disseminates a new set of guidelines on the evaluation and management of venous thromboembolic disease (VTE). The ACCP just released its updated guidelines for the treatment of VTE and I…
Read More
More Articles – Anticoagulation, Deep venous thrombosis, HPC Updates, Pulmonary Embolism, venous thromboembolism
The new direct target-specific oral anticoagulants (TSOACs; dabigatran, rivaroxaban, apixaban, and edoxaban) have been compared with vitamin K antagonists (VKAs; warfarin and similar agents) for acute venous thromboembolism (VTE) in six recent phase III clinical trials encompassing more than 27,000…
Read More
Compared with warfarin, the new agents significantly reduced all-cause and vascular mortality. The new direct-acting oral anticoagulants (DOACs; dabigatran, rivaroxaban, apixaban, and edoxaban) have been found to be noninferior to vitamin K antagonists in clinical trials of stroke prevention in…
Read More